Lundbeck invests in Ossianix for neurological drugs

01/3/2012 | Reuters

Ossianix received a convertible promissory note from H. Lundbeck to help it develop biopharmaceutical agents for the central nervous system. Lundbeck has negotiation rights for certain medicines and technology resulting from the project. Separately, Lundbeck rolled out epilepsy treatment Onfi in the U.S.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID